Improving MRI techniques for pancreatic cancer diagnosis
Fully Quantitative Low-Dose, Motion-Resolved Dynamic Contrast-Enhanced MRI in Pancreatic Adenocarcinoma
This study is testing a new type of MRI that uses less radiation and can better see how pancreatic cancer is changing, making it safer and more accurate for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-11142157 on NIH RePORTER |
What this research studies
This research focuses on enhancing MRI technology to better diagnose and monitor pancreatic adenocarcinoma by using a low-dose, motion-resolved dynamic contrast-enhanced MRI approach. It aims to accurately measure tissue characteristics related to blood flow and inflammation, which are crucial for understanding the disease's progression. The study will involve advanced imaging techniques that account for patient movement, such as heartbeats and breathing, to ensure clearer and more reliable results. By utilizing a gadolinium-based contrast agent, the research seeks to improve the safety and effectiveness of MRI scans for patients with pancreatic cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pancreatic adenocarcinoma who require imaging for treatment planning or monitoring.
Not a fit: Patients with other types of cancer or those who do not require MRI imaging for their condition may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to earlier and more accurate diagnoses of pancreatic cancer, improving treatment outcomes for patients.
How similar studies have performed: Previous research has shown promise in using advanced MRI techniques for cancer diagnosis, indicating that this approach could yield significant advancements.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Christodoulou, Anthony G — University of California Los Angeles
- Study coordinator: Christodoulou, Anthony G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.